Accretion Pharmaceuticals IPO Financials
The Accretion Pharmaceuticals IPO provide an overview of the company's performance over the previous financial periods. Investors can evaluate key financial metrics such as assets, revenue, profit after tax (PAT), net worth, reserves & surplus, and total borrowings to assess the company's financial strength, profitability, and long-term growth potential before investing in the IPO.
As of 30 Sep 2024, Accretion Pharmaceuticals Limited reported assets of ₹29.34 crore, revenue of ₹11.89 crore, and a profit after tax (PAT) of ₹1.57 crore. The company had a net worth of ₹9.91 crore and reserves & surplus of ₹1.74 crore, while total borrowings remained nil, indicating a debt-free balance sheet.
Revenue increased by 185.45% in 31 Mar 2024 and decreased by 12.99% in 31 Mar 2023 and decreased by 23.54% in 31 Mar 2022, while Profit After Tax (PAT) grew by 147.13% in 31 Mar 2024 and declined by 97.42% in 31 Mar 2023 and declined by 20.00% in 31 Mar 2022, respectively.
*Info is indicative. Not an Investment Advice. Grey market trading is unregulated.
Accretion Pharmaceuticals Limited Financials (₹ in Crores)
| Particular | 30 Sep 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|---|
| Assets | 29.34 | 27.05 | 20.58 | 17.74 |
| Revenue | 11.89 | 33.94 | 29.53 | 22.58 |
| Profit After Tax | 1.57 | 3.88 | 0.1 | 0.08 |
| Net Worth | 9.91 | 5.35 | 3.84 | 3.08 |
| Reserve & Surplus | 1.74 | 1.35 | 0 | 0 |
| Total Borrowings | 0 | 0 | 0 | 0 |
EPS Pre
4.74%
EPS Post
2.82%
P/E Pre
21.29
P/E (Post Issue)
35.82x
Company Financial Information
Disclaimer: This data is for informational purposes only and does not constitute investment advice. Figures shown are illustrative sample data.
Frequently Asked Questions
Everything you need to know before applying to an IPO.
What is the Revenue of Accretion Pharmaceuticals Limited?
Accretion Pharmaceuticals Limited reported revenue of ₹11.89 crore as of 30 Sep 2024. Revenue figures from the Accretion Pharmaceuticals IPO provide insights into sales growth, market demand, and business scalability.
What is the Profit After Tax (PAT) of Accretion Pharmaceuticals Limited?
Accretion Pharmaceuticals Limited reported a Profit After Tax (PAT) of ₹1.57 crore as of 30 Sep 2024. PAT represents the company's net profit after deducting all operating expenses, interest, taxes, and other applicable charges, making it a key indicator of overall profitability.
What is the PE Ratio of Accretion Pharmaceuticals Limited?
Accretion Pharmaceuticals Limited has a Price-to-Earnings (P/E) ratio of 21.29x based on the IPO issue price. The P/E ratio compares the company's share price with its earnings per share (EPS) and is a commonly used valuation metric to assess whether a stock is fairly valued relative to its earnings and industry peers.